EUVIMEDEUVIMED entdecken
Leitlinie

World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults

Francesca Celletti, Jeremy Farrar, Luz De Regil

JAMA · 03.02.2026 · 335 (5) · 434

DOI: 10.1001/jama.2025.24288 ↗

Kurz gefasst

Leitlinie in der Zeitschrift JAMA, erschienen am 03.02.2026. Verfasst von Francesca Celletti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Senior Advisor, Obesity, Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity. Die Arbeit wurde bisher 172-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Obesity is a chronic, relapsing disease affecting over 1 billion people worldwide, driving substantial morbidity, mortality, and economic burden. Glucagon-like peptide-1 therapies (GLP-1 therapies) provide clinically meaningful weight loss and broad metabolic benefits. In response to Member State requests, the World Health Organization (WHO) has issued guidelines for adults living with obesity. Observations The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities. WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits. Both recommendations were graded conditional , reflecting that GLP-1 therapies—with or without behavioral therapy—are effective, but limited long-term data, cost, system readiness, equity, variability in patient priorities, and context-specific feasibility remain considerations. Implementation of these guidelines depends on equitable access to affordable therapies, health system preparedness, and most importantly assurance that care is person-centered, nondiscriminatory, and universally accessible. Given the time required to implement these measures, a priority is a transparent, equitable, evidence-based framework to identify those at highest need while allowing incremental expansion of eligibility as access, capacity, and readiness evolve; this will be the next focus of the WHO guideline. Conclusions and Relevance Medication alone cannot solve the global obesity burden. The availability of GLP-1 therapies should galvanize the global community to build a fair, integrated, and sustainable obesity ecosystem. Countries must ensure equitable access not only to comprehensive disease management, but also to health promotion and prevention policies and interventions targeting the general population and those at high risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1ObesityAdultHumansBehavior TherapyWorld Health OrganizationHealth PromotionGlobal Burden of DiseasePatient-Centered CareHealth Services Accessibility

Substanzen

Glucagon-Like Peptide 1

Autor:innen und Institutionen

  • Senior Advisor, Obesity, Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland.
  • Assistant Director General, Health Promotion, Prevention, and Care, World Health Organization, Geneva, Switzerland.
  • Director, Department of Nutrition and Food Safety, World Health Organization, Geneva, Switzerland.

Förderung

  • World Health Organization

Zitieren

APA

Celletti, F., Farrar, J., & De Regil, L. (2026). World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA, 335(5), 434. https://doi.org/10.1001/jama.2025.24288

Vancouver

Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026;335(5):434. doi:10.1001/jama.2025.24288

BibTeX
@article{Celletti2026,
  author = {Celletti, Francesca and Farrar, Jeremy and De Regil, Luz},
  title = {World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {5},
  pages = {434},
  doi = {10.1001/jama.2025.24288}
}
Kostenlos starten →